

# Katarina Nikolic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11409195/publications.pdf>

Version: 2024-02-01

30  
papers

1,332  
citations

516710

16  
h-index

454955

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2591  
citing authors

#	ARTICLE	IF	CITATIONS
1	A perspective on multi-target drug discovery and design for complex diseases. <i>Clinical and Translational Medicine</i> , 2018, 7, 3.	4.0	481
2	Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017, 151, 4-34.	5.7	128
3	Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2014, 75, 82-95.	5.5	109
4	One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. <i>Frontiers in Neuroscience</i> , 2016, 10, 177.	2.8	75
5	In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. <i>Frontiers in Chemistry</i> , 2019, 7, 873.	3.6	71
6	Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies. <i>Frontiers in Neuroscience</i> , 2016, 10, 265.	2.8	62
7	<i>N</i> -Methyl- <i>N</i> -((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1 <i>H</i> -indol-2-yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10455-10463.	6.4	56
8	Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1893.	4.3	35
9	QSAR study of imidazoline antihypertensive drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7134-7140.	3.0	30
10	Procognitive Properties of Drugs with Single and Multitargeting H <sub>3</sub> Receptor Antagonist Activities. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 613-623.	3.9	29
11	17 $\beta$ -carboxamide steroids – in vitro prediction of human skin permeability and retention using PAMPA technique. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 52, 95-108.	4.0	28
12	Prediction of blood-brain barrier permeation of $\alpha$ -adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 68, 94-105.	4.0	28
13	Partial Least Square and Hierarchical Clustering in ADMET Modeling: Prediction of Blood-brain Barrier Permeation of $\alpha$ -Adrenergic and Imidazoline Receptor Ligands. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 622.	2.1	24
14	Prediction of hepatic microsomal intrinsic clearance and human clearance values for drugs. <i>Journal of Molecular Graphics and Modelling</i> , 2009, 28, 245-252.	2.4	22
15	Biopartitioning micellar chromatography as a predictive tool for skin and corneal permeability of newly synthesized 17 $\beta$ -carboxamide steroids. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 105-112.	4.0	20
16	Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1542-1555.	2.4	18
17	Application of in vitro PAMPA technique and in silico computational methods for blood-brain barrier permeability prediction of novel CNS drug candidates. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 168, 106056.	4.0	18
18	Predicting targets of compounds against neurological diseases using cheminformatic methodology. <i>Journal of Computer-Aided Molecular Design</i> , 2015, 29, 183-198.	2.9	16

#	ARTICLE	IF	CITATIONS
19	Quantitative structure–mobility relationship analysis of imidazoline receptor ligands in CD-mediated CE. Electrophoresis, 2013, 34, 471-482.	2.4	13
20	Pharmacophore modeling, drug design and virtual screening on multi-targeting procognitive agents approaching histaminergic pathways. Journal of the Taiwan Institute of Chemical Engineers, 2015, 46, 15-29.	5.3	11
21	Application of biopartitioning micellar chromatography and QSRR modeling for prediction of gastrointestinal absorption and design of novel 1 <sup>2</sup> -hydroxy-1 <sup>2</sup> -arylalkanoic acids. European Journal of Pharmaceutical Sciences, 2017, 100, 280-284.	4.0	10
22	ESTIMATION OF LIPOPHILICITY AND RETENTION BEHAVIOR OF SOME ALPHA ADRENERGIC AND IMIDAZOLINE RECEPTOR LIGANDS USING RP-TLC. Journal of Liquid Chromatography and Related Technologies, 2014, 37, 2829-2845.	1.0	8
23	The Quantitative Structure–Retention Relationship (QSRR) Analysis of Some Centrally Acting Antihypertensives and Diuretics. QSAR and Combinatorial Science, 2008, 27, 1036-1044.	1.4	7
24	An Experimental Design Approach to Selecting the Optimum HPLC Conditions for the Determination of 2-Arylimidazoline Derivatives. Journal of Liquid Chromatography and Related Technologies, 2009, 32, 656-667.	1.0	7
25	Quantitative structure-retention relationship modeling of the retention behavior of guanidine and imidazoline derivatives in reversed-phase thin-layer chromatography. Journal of Planar Chromatography - Modern TLC, 2015, 28, 119-125.	1.2	7
26	In vitro prediction of gastrointestinal absorption of novel 1 <sup>2</sup> -hydroxy-1 <sup>2</sup> -arylalkanoic acids using PAMPA technique. European Journal of Pharmaceutical Sciences, 2017, 100, 36-41.	4.0	6
27	Determination of Moxonidine and Its Impurities by Thin-Layer Chromatography. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 1121-1125.	1.0	4
28	A Comparative Study of Chromatographic Behavior and Lipophilicity of Selected Imidazoline Derivatives. Journal of Chromatographic Science, 2016, 54, 1137-1145.	1.4	3
29	Evaluation of Biological Activity and Computer-Aided Design of New Soft Glucocorticoids. Archiv Der Pharmazie, 2017, 350, 1600383.	4.1	3
30	Current computer-aided drug design methodologies in discovery of novel drug candidates for neuropsychiatric and inflammatory diseases. Arhiv Za Farmaciju, 2021, 71, 225-256.	0.5	0